Keros Therapeutics, Inc. announced on May 29, 2025, the discontinuation of all development of cibotercept in pulmonary arterial hypertension (PAH) following the analysis of safety and efficacy data from the TROPOS Phase 2 clinical trial. The trial had been previously halted due to observations of pericardial effusion adverse events.
In connection with this decision and an assessment of its ongoing development programs, Keros' Board of Directors and management team decided to implement a corporate restructuring. This restructuring includes a reduction in the company’s headcount by approximately 45%, resulting in 85 full-time employees.
Keros expects to realize average annualized cost savings of approximately $17 million from these actions. The company stated that this move aligns operations with ongoing strategic priorities, focusing resources on its key development programs, particularly KER-065.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.